期刊
BLOOD REVIEWS
卷 31, 期 5, 页码 318-327出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2017.05.002
关键词
Obinutuzumab; Ocaratuzumab; Ofatumumab; Rituximab; Ublituximab; Veltuzumab
类别
The anti-CD20 antibodies represent a major advancement in the therapeutic options available for chronic lymphocytic leukemia. The addition of rituximab, ofatumumab and obinutuzumab to various chemotherapy regimens has led to considerable improvements in both response and survival. Ocaraturtimab, veltuzumab and ublituximab are currently being explored within the trial setting. We review the current status of these antibodies, and discuss how their mechanisms of action may impact on the choice of combinations with novel small molecule agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据